Skip to main content
Swing Capital

Caplin Point Laboratories Ltd

NSE: CAPLIPOINT BSE: 524742

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]

₹1,998
52W: ₹1500 — ₹2397
PE 38.3 · Book ₹270 · +640% vs book
Market Cap₹15,187 Cr
Stock P/E38.3Price to Earnings
ROCE27%Return on Capital
ROE21.1%Return on Equity
Div. Yield0.3%Face Value ₹2

Strengths

  • +Company is almost debt free.
  • +Company has delivered good profit growth of 21.2% CAGR over last 5 years

Weaknesses

  • −Stock is trading at 7.34 times its book value
  • −The company has delivered a poor sales growth of 8.87% over past five years.
  • −Earnings include an other income of Rs.195 Cr.
  • −Debtor days have increased from 97.2 to 131 days.
  • −Working capital days have increased from 161 days to 309 days

Shareholding Pattern

Promoters70.57%
FIIs6.15%
DIIs2.14%
Public21.14%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters70.56%70.56%70.56%70.56%70.56%70.57%▲0.070.57%70.57%
FIIs3.38%3.71%▲0.34.86%▲1.25.73%▲0.96.16%▲0.46.51%▲0.36.58%▲0.16.15%▼0.4
DIIs1.49%1.83%▲0.32.11%▲0.32%▼0.12.22%▲0.22.1%▼0.12.05%▼0.12.14%▲0.1
Public24.59%23.93%▼0.722.48%▼1.421.72%▼0.821.06%▼0.720.82%▼0.220.81%▼0.021.14%▲0.3

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales133139186208185174183175189191
Expenses708210411010899969998108
Operating Profit63588198777587769284
OPM %48%41%44%47%42%43%47%43%48%44%
Net Profit55707310675868610387110
EPS ₹7.39.29.5413.919.8311.3811.313.511.4814.41

AI Insights

Revenue Trend

Mar 2026 revenue at ₹738Cr, down 1.9% YoY. OPM at 46%.

Debt Position

Borrowings at ₹2Cr. Debt-to-equity ratio: 0.00x. Healthy balance sheet.

Capex Cycle

CWIP at ₹9Cr (4% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 2.14% (+1.87pp change). FIIs: 6.15% (+3.47pp change). Promoters hold 70.57%.

Margin & Efficiency

ROCE declining from 64% (Jun 2015) to 27% (Mar 2026). Working capital days: 309.

Valuation

PE 38.3x with 27% ROCE. Price is 640% above book value of ₹270. Dividend yield: 0.3%.

Recent Announcements